According to an article in U. S. News and World Report, an experimental drug called ADI-PEG20 increased average survival of mesothelioma patients by 1.6 months, and quadrupled the three-year survival rate, when combined with traditional chemotherapy, trial results show.
These findings are significant because malignant mesothelioma has one of the lowest five-year survival rates of any solid cancer, around 5% to 10%, researchers said
ADI-PEG20 works by cutting off the cancer’s food supply, researchers explained. The drug blocks the ability of cancer cells to absorb the amino acid arginine from the bloodstream.
If you or a loved one has been diagnosed with mesothelioma as a result of exposure to asbestos, contact the experienced attorneys at Nass Cancelliere. For more than 40 years, the Philadelphia-based law firm of NASS CANCELLIERE has represented over 5,000 people who have contracted MESOTHELIOMA and other forms of asbestos-related illness. Our attorneys have tried over 1,000 cases throughout Pennsylvania and New Jersey and we have collected over $500 million for our clients. Learn more by calling 215-546-8200 to speak with an attorney or contacting us online.
1500 JFK Blvd. (Two Penn Center), Suite 404
Philadelphia, PA 19102